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Objectives: This study was designed to examine the myocardial protective effect of
leukocyte-depleted terminal blood cardioplegia in association with nitric oxide and
peroxynitrite production, especially for patients undergoing prolonged aortic cross-
clamping.
Methods: Fifty-four patients (34 men, 20 women, mean age 56.7  12.7 years)
undergoing aortic valve replacement were randomly allocated to one of two groups;
group LDTC (n  27) received 10 minutes of leukocyte-depleted terminal blood
cardioplegic solution, and group CONT (n 27) served as controls. Each group was
subdivided into 2 groups: aortic crossclamping for less than 120 minutes in groups
LDTC-S (n  13) and CONT-S (n  14); aortic crossclamping for 120 minutes or
more in groups LDTC-L (n  14) and CONT-L (n  13).
Results: After aortic unclamping, group LDTC-L showed higher incidence of
spontaneous defibrillation (78.6% vs 30.8%, P  .0213), higher plasma nitrate 
nitrite in the coronary sinus effluent (32.5  4.1 vs 28.7  3.0 mol/L, P  .0013),
lower differences between coronary sinus effluent and arterial blood in the percent-
age ratio of nitrotyrosine to tyrosine (myocardium-derived peroxynitrite; 2.987% 
0.576% vs 3.951%  0.952%, P  .0036), and plasma polymorphonuclear-elastase
(113.9 21.3 vs 155.5 41.6 g/L, P .0029) and malondialdehyde (2.75 0.67
vs 4.02  0.96 mol/L, P  .0005) than group CONT did. Postoperatively, group
LDTC-L showed lower human-heart fatty acid–binding protein (111.4  25.2 vs
156.4 38.6 IU/L, P .0013), lower creatine kinase–muscle and brain (19.2 4.7
vs 24.8  6.5 IU/L, P  .0120), and smaller requirement of catecholamine (5.44 
2.29 vs 8.45  3.42 g · kg1 · min1, P  .0122). There were no significant
differences in these parameters between groups LDTC-S and CONT-S.
Conclusions: This study demonstrated that leukocyte-depleted terminal blood car-
dioplegia provided superior myocardial protective effects and regulated myocardial-
derived nitric oxide and peroxynitrite production only for patients undergoing aortic
crossclamping for more than 120 minutes. The results suggest that prolonged aortic
crossclamping deteriorates the tolerance to leukocyte-mediated myocardial injury
accompanied by endothelial dysfunction associated with nitric oxide and peroxyni-
trite production.
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Recent advances in myocardial protectionhave lessened the chances of perioperativecardiogenic collapse and have providedsatisfactory results associated with im-proved morbidity and mortality. Neverthe-less, intraoperative myocardial dysfunction
can occur in compromised hearts (such as severe left ven-
tricular hypertrophied hearts or preoperative ischemic-in-
jured hearts) because the tolerance to myocardial damage is
deteriorated in such hearts.1,2 A long period of cardioplegic
arrest is also a crucial factor that deteriorates the tolerance
to perioperative myocardial injury.3,4 The mechanism of
cardioplegic myocardial protection is based on the delay of
the degradative process and the conservation of limited
cellular energy, and thus, ischemic myocardial damage de-
velops even under cardioplegic arrest. In addition, cardio-
pulmonary bypass (CPB) induces blood activation through
the contact with artificial surfaces of the bypass circuit.5 An
influx of CPB-induced chemotactic mediators to the coro-
nary vessels around the reperfusion period can largely in-
fluence the severity of perioperative myocardial damage,
and the production of cytotoxic mediators increases accord-
ing to the duration of CPB involving cardioplegic arrest.5
Neutrophils are thought to play a pivotal role in the
development of myocardial ischemia-reperfusion injury.6-9
Myocardial reperfusion after a period of ischemia induces a
series of interactions between neutrophils and endothelial
cells as follows: endothelial cell dysfunction, neutrophil
adherence, myocardial infarction and apoptosis, and to
some extent myocardial stunning.8 On the other hand, acti-
vated neutrophils themselves release cytotoxic chemotactic
mediators, such as polymorphonuclear-elastase (PMNE),
superoxide anion, myeloperoxidase, and proinflammatory
cytokines.9 “Leukocyte depletion” has been suggested as a
controlled myocardial reperfusion method, and we clini-
cally demonstrated the efficacy of leukocyte-depleted ter-
minal blood cardioplegia (LDTC) in the attenuation of
perioperative myocardial injury especially for patients with
a hypertrophied heart or a heart severely injured by preop-
erative ischemic insults.10,11 This modification around the
reperfusion period can also be applicable to the cases re-
quiring a long duration of aortic crossclamping (AXC).
Nitric oxide (NO) is an inflammation-mediated vasoac-
tive substance and plays both cytoprotective and cytotoxic
roles in the development of inflammation.12 Myocardium
subjected to ischemia is reported to enhance NO production
in the early phase.13,14 However, endogenous NO produc-
tion decreases at myocardial reperfusion, which is thought
to accelerate intraoperative myocardial damage.15-18 In clin-
ical circumstances, CPB-activated neutrophils enhance
myocardial endothelial damage and further reduces endog-
enous NO production. Therefore, LDTC appears to attenu-
ate intraoperative endothelial damage associated with myo-
cardial-derived NO and its related metabolites such as
peroxynitrite (ONOO), which has not yet been elucidated.
To examine the hypothesis that prolonged AXC participates
in neutrophil-mediated deterioration of the tolerance to
myocardial injury, we evaluated the myocardial protective
effects of LDTC in reference to NO and ONOO produc-
tion for patients requiring prolonged AXC.
Methods and Materials
Study Population and Operative Procedures
Fifty-four patients undergoing elective aortic valve replacement in
our institution between 1997 and 2000 were enrolled in this study.
Thirty-four were men and 20 were women, and their ages at
operation ranged from 18 to 73 years with a mean of 56.7  12.7
year. Twenty had aortic stenosis, 29 had aortic regurgitation, and
5 had both. Exclusion criteria was as follows: reoperation, con-
comitant mitral valve disease to be surgically treated, coronary
artery disease requiring revascularization, and severe left ventric-
ular hypertrophy shown as left ventricular mass index (LVMI)
over 150 g/m2 by echocardiography. None received nitroglycerin
before, during, or after CPB for the duration of the study period.
All patients gave their informed consent to participate in this study,
and we followed the guidelines of our internal review board. The
investigation conforms to the principles outlined in the Helsinki
Declaration.
These patients were randomly divided into 2 groups; 10 min-
utes of LDTC was done followed by aortic unclamping in group
LDTC (n  27). Group CONT (n  27) served as controls and
terminal cardioplegia was not applied. Each group was subdivided
into 2 groups according to AXC time (mean 126.1  31.2 min-
utes). AXC time was under 120 minutes (AXC  120 minutes) in
groups LDTC-S (n  13) and CONT-S (n  14) and was 120
minutes or more (AXC  120 minutes) in groups LDTC-L (n 
14) and CONT-L (n  13).
Anesthesia was induced and maintained with diazepam, fenta-
nyl, and inhaled isoflurane. Heparin at a dose of 3 mg/kg was
infused, and CPB was instituted in a routine fashion. Two venous
cannulas were placed directly into the superior vena cava and the
inferior vena cava. An arterial cannula was positioned directly into
the ascending aorta or the right subclavian artery. The CPB circuit
was composed of a centrifugal pump, a membrane oxygenator, an
arterial filter, a venous reservoir, and tubing lines, which were
primed without blood components. No component of the CPB
circuit was heparin-coated. CPB was controlled by -stat manage-
ment with blood-flow rates of 2.2 to 2.6 L/min/m2 to maintain
mean arterial pressure between 60 and 80 mm Hg, using vasoac-
tive agents such as chlorpromazine hydrochloride and norepineph-
rine if necessary. We measured the temperature of blood in the
arterial line just after it passed through the heat exchanger and
controlled it at 34°C. To reduce CPB-induced inflammatory re-
sponse, 300,000 units of aprotinin (Trasylol; Bayer, Leverkusen,
Germany)19 was added into venous reservoir at the initiation of
CPB.
Intraoperative myocardial protection was achieved by initial
and intermittent cold blood cardioplegia (BCP) administration, as
previously described.20 Cardiac arrest was achieved by aortic
crossclamping and an initial cold BCP administration (blood:
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crystalloid  2:1, 16 mEq/L potassium and 0.8 to 1.0 mEq/L of
calcium) at a volume of 3.0 mL/g of left ventricular (LV) mass.
Initial BCP was infused retrogradely into the coronary sinus until
the aortotomy, at which point the remaining dose was infused in a
selective antegrade fashion. A 4:1–blood:crystalloid BCP at a dose
of 1.5 mL/g of LV mass was infused every 20 minutes as an
intermittent BCP. The temperature of the BCP solution was main-
tained at 15°C to 20°C. The myocardial temperature at the LV
apex was monitored and maintained below 20°C by additional
infusions of cardioplegic solution.
A leukocyte-removal filter (BC-1; Pall, East Hills, NY) was
incorporated into the cardioplegic solution administration system
just after the oxygenator reservoir for leukocyte depletion.21 For
patients in group LDTC, leukocyte-depleted oxygenated blood was
mixed with crystalloid cardioplegic solution (blood:crystalloid 
4:1) and infused at a flow rate of 1.0 mL/min/g of LV mass with
a perfusion pressure of less than 50 mm Hg for 10 minutes. The
LDTC temperature was set at 30°C at induction and was increased
immediately to 36°C. At the end of LDTC perfusion, the aorta was
unclamped and the heart was reperfused with oxygenated whole
blood in the conventional manner.
The patients were rewarmed after aortic unclamping, and CPB
was terminated when rectal temperatures reached 35°C. Subse-
quent administrations of catecholamine were performed as needed
based on the patient’s hemodynamic condition after the termina-
tion of CPB.
Measurements
In group LDTC, oxygenated blood for the cardioplegic solution
was sampled just before aortic unclamping from both the inlet and
outlet of the leukocyte-removal filter. To evaluate the efficiency of
leukocyte depletion, leukocyte count and differential count for
neutrophils were determined, and the depletion ratios were calcu-
lated.
Arterial blood (Ao) and coronary sinus effluent blood (CS)
were obtained simultaneously before the initiation of CPB and at
5 minutes after aortic unclamping. Plasma PMNE levels were
measured using enzyme immunoassay to evaluate the degree of
neutrophil activation. Plasma PMNE in Ao was considered CPB-
induced neutrophil activation, and the difference in plasma PMNE
between CS and Ao (CS-Ao difference in PMNE) was considered
reperfusion-induced neutrophil activation. Plasma nitrate  nitrite
(NOx), major end products of NO, were measured as a marker of
NO production by the method based on the Griess reaction. Plasma
levels of nitrotyrosine and tyrosine were measured using a high-
pressure liquid chromatography (HPLC) method. The percentage
ratio of nitrotyrosine to tyrosine ([nitrotyrosine/(tyrosine  nitro-
tyrosine)]  100%; %NO2-Tyr) was considered ONOO produc-
tion, and the difference in %NO2-Tyr between CS and Ao (CS-Ao
difference in %NO2-Tyr) was used as an index of myocardium-
derived ONOO.22 Plasma levels of malondialdehyde (MDA)
were measured using the ion-pairing HPLC method, and the dif-
ference between CS and Ao (CS-Ao difference in MDA) was used
as an index of myocardial lipid peroxidation mediated by oxygen
radicals.
The rate of spontaneous defibrillation and the maximum dose
of catecholamine (dopamine plus dobutamine) during the postop-
erative period were used as clinical parameters to evaluate myo-
cardial protective effects. The CS-Ao difference in PMNE, CS-Ao
difference in MDA, plasma human-heart fatty acid–binding pro-
tein (HH-FABP), and peak plasma creatine kinase–muscle and
brain (peak CK-MB) were used as biochemical indicators of
perioperative myocardial damage after cardiac surgical proce-
dures.20,21 Plasma HH-FABP was measured at 45 minutes after
myocardial reperfusion using a sandwich enzyme immunoassay.
Plasma CK-MB was measured every 6 hours after operation using
immunoinhibition assay, and the maximum value during the first
24 postoperative hours was used as peak CK-MB.
Statistical Analysis
All data are expressed as mean  standard deviation (SD). Statis-
tical correlations were indicated by Pearson correlation coefficient
test and simple regression analysis. Chi-square test for indepen-
dence, one-factor analysis of variance, and unpaired Student t test
were used to compare values between the groups. All analyses
were performed with the Statview v5.0 statistical package (Abacus
Concepts Inc, Berkeley, Calif). A P value of less than .05 was
considered statistically significant.
Results
Patient Characteristics and Clinical Outcomes
There were no significant differences in the patient data
such as age at operation, sex, body weight, body surface
area, LVMI, aortic valvular disease, concomitant aortic
disease, CPB time, and AXC time between groups CONT-S
and LDTC-S and between groups CONT-L and LDTC-L
(Table 1).
All patients in this study tolerated the surgical proce-
dures and were discharged without any complications re-
lated to cardioplegic solution administration. Perioperative
myocardial infarction was not observed in either group, and
no cardiogenic shock requiring circulatory assist device
occurred. There was no mortality, and none fell into cardiac
failure late after hospital discharge.
Depletion Efficiency of Leukocytes and Neutrophils
At the end of LDTC reperfusion, the efficiency of leukocyte
depletion was 94.6%  2.4% and that of neutrophil deple-
tion was 93.5%  1.9%.
Correlation between AXC Time and Plasma PMNE in
the Arterial Blood
Plasma PMNE level in Ao was significantly correlated with
AXC time in overall patients (r  .913, P  .0001; Figure
1, a). There was no significant difference in plasma PMNE
between groups CONT-S and LDTC-S (CONT-S vs
LDTC-S: 574.5  77.3 vs 565.0  69.8 g/L, P  .7411)
and between groups CONT-L and LDTC-L (CONT-L vs
LDTC-L: 813.5  83.8 vs 785.5  107.9 g/L, P  .4601;
Figure 1, b).
Plasma NOx in Ao and CS (before CPB and after AXC)
Plasma NOx before CPB did not differ significantly be-
tween Ao and CS in each group ([Ao vs CS] CONT-S: 27.3
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 2.9 vs 27.5  2.7 mol/L, P  .8517; LDTC-S: 26.4 
2.5 vs 27.3 2.0 mol/L, P .4358; CONT-L: 26.4 3.0
vs 26.9  3.3 mol/L, P  .6896; LDTC-L: 27.5  3.2 vs
26.6  2.7 mol/L, P  .4285). Five minutes after aortic
unclamping, plasma NOx in CS was significantly lower
than that in Ao in all groups ([CS vs Ao] CONT-S: 32.3 
4.1 vs 30.4  3.2 mol/L, P  .0183; LDTC-S: 33.6  4.8
vs 31.5  4.0 mol/L, P  .0237; CONT-L: 35.2  4.5 vs
28.7  3.0 mol/L, P  .0001; LDTC-L: 35.6  5.1 vs
32.5  4.1 mol/L, P  .0088). Plasma NOx levels in both
Ao and CS were significantly higher after reperfusion than
before ischemia in all groups (P  .0001 in each group).
Plasma NOx in CS after reperfusion was significantly
higher in group LDTC-L (32.5 4.1 mol/L) than in group
CONT-L (28.7  3.0 mol/L, P  .0013), whereas there
was no significant difference between groups LDTC-S (31.5
 4.0 mol/L) and CONT-S (30.4  3.2 mol/L, P 
.4358; Figure 2).
%NO2-Tyr in Ao and CS (before CPB and after AXC)
Nitrotyrosine was not detected in the supernatant of either
sample obtained before CPB. Five minutes after aortic un-
clamping in all groups, it was detected in both samples of
Ao and CS, and %NO2-Tyr in CS was significantly higher
than that in Ao (P  .0001 in each group). Group LDTC-L
showed a significantly lower %NO2-Tyr in CS (3.35% 
0.65% vs 4.18%  0.77%, P  .0055) and a significantly
lower CS-Ao difference in %NO2-Tyr (2.987%  0.576%
vs 3.951%  0.952%, P  .0036) than group CONT-L did,
whereas there were no significant differences in %NO2-Tyr
TABLE 1. Patient characteristics and cardiopulmonary bypass data (mean  SD)
Group CONT-S
(n  14)
Group LDTC-S
(n  13)
Group CONT-L
(n  13)
Group LDTC-L
(n  14)
Age (years) 53.9 11.6 54.8 12.2 57.4 17.4 60.6 9.1
Sex (men/women) 8/6 10/3 8/5 8/6
Body weight (kg) 59.2 15.2 63.6 17.1 53.7 10.2 55.3 13.3
Body surface area (m2) 1.64 0.24 1.65 0.25 1.57 0.21 1.56 0.20
Left ventricular mass index (g/m2) 119.2 12.7 122.9 13.9 125.6 18.7 127.1 11.3
Aortic valvular disease
Aortic stenosis 2 3 7 8
Aortic regurgitation 11 9 4 5
Aortic stenosis and regurgitation 1 1 2 1
Concomitant aortic disease
Annulo-aortic ectasia 0 0 1 1
Aneurysm of the ascending aorta 1 1 1 1
Cardiopulmonary bypass time (minutes) 135.5 14.5 137.7 16.4 184.1 15.4*,† 191.6 16.7*,†
Aortic crossclamping time (minutes) 98.4 12.7 99.7 12.1 149.3 18.0*,† 156.7 17.5*,†
*P  .01 vs group CONT-S.
†P  .01 vs group LDTC-S.
Figure 1. a, Relation between the aortic crossclamping time (AXC time) and plasma level of polymorphonuclear-
elastase in the arterial blood (PMNE in Ao) (PMNE in Ao 156.189 4.189 AXC time; R2 .834). b, Comparisons
of PMNE in Ao among the 4 groups. Data are expressed as mean  SD. *P < .0001 vs CONT-S or LDTC-S.
Cardiopulmonary Support and Physiology Hayashi et al
1816 The Journal of Thoracic and Cardiovascular Surgery ● December 2003
CSP
in CS (2.31% 0.45% vs 2.56% 0. 56%, P .1347) and
CS-Ao difference in %NO2-Tyr (1.785%  0.127% vs
2.001%  0.558%, P  .1077) between groups LDTC-S
and CONT-S (Figure 2, b, and Figure 3). The CS-Ao
difference in %NO2-Tyr was significantly correlated with
AXC time (group LDTC: r  .899, P  .0001; group
CONT: r  .933, P  .0001) and the CS-Ao difference in
PMNE (group LDTC: r  .893, P  .0001; group CONT:
r  .820, P  .0001; Figure 4).
Clinical and Biochemical Parameters Associated with
Myocardial Protection
The percentage ratio of patients with spontaneous defibril-
lation after aortic unclamping was significantly higher and
the maximum catecholamine dose during the postoperative
period was significantly smaller in group LDTC-L than in
group CONT-L. There were no significant differences in
these parameters between groups LDTC-S and CONT-S
(Table 2).
Five minutes after aortic unclamping, group LDTC-L
showed significantly smaller CS-Ao difference in PMNE
(113.9  21.3 vs 155.5  41.6 g/L, P  .0029), CS-Ao
difference in MDA (2.75  0.67 vs 4.02  0.96 mol/L, P
 .0005), HH-FABP (111.4  25.2 vs 156.4  38.6 IU/L,
P  .0013), and peak CK-MB (19.2  4.7 vs 24.8  6.5
IU/L, P  .0120) than group CONT-L. Between groups
LDTC-S and CONT-S, however, there were no significant
differences in these parameters (PMNE: 83.8 16.1 vs 96.5
 26.5 g/L, P .1472; MDA: 1.51 0.43 vs 1.95 0.86
mol/L, P .2462; HH-FABP: 82.3 16.8 vs 95.2 23.8
IU/L, P  .1187; CK-MB: 12.0  3.1 vs 13.1  4.2 IU/L,
P  .4263; Figure 5).
Discussion
In this clinical study, LDTC-treated patients with AXC of
120 minutes or more showed a significantly higher percent-
age of spontaneous defibrillation after aortic unclamping,
lower CS-Ao differences in PMNE and MDA after reper-
fusion, lower postoperative HH-FABP and peak CK-MB,
and smaller dosage of catecholamine requirement than
LDTC-untreated patients with AXC of 120 minutes or
more. As for NO production, plasma NOx level in CS was
significantly higher and the CS-Ao difference in %NO2-Tyr
was significantly lower in the LDTC-treated patients with
AXC of 120 minutes or more than in the LDTC-untreated
patients with AXC of 120 minutes or more. On the other
hand, significant differences in these above parameters were
not observed between the LDTC-treated and LDTC-un-
treated patients undergoing AXC for less than 120 minutes.
Figure 2. Changes in the plasma levels nitrate  nitrite (NOx) in the blood obtained from aortic root and coronary
sinus, before cardiopulmonary bypass and 5 minutes after aortic unclamping. Data are expressed as mean  SD.
*P < .0001 vs Ao before ischemia or CS before ischemia.
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Regarding neutrophil activation during reperfusion, ara-
chidonate cascade and xanthine-xanthine oxidase system
are thought to play pathophysiologically crucial roles in the
development of myocardial ischemia-reperfusion inju-
ry.23,24 The activation of arachidonate cascade induces the
release of various chemotropism substances, which activate
circulating neutrophils during reperfusion.24 A large amount
of free radicals produced from myocardium at reperfusion
through xanthine-xanthine oxidase system also activates
circulating neutrophils.23 Prolonged AXC further activates
arachidonate cascade and xanthine-xanthine oxidase sys-
tem, which enhances CPB-induced neutrophil activation.
Therefore, the duration of cardioplegic arrest largely affects
the severity of neutrophil-mediated intraoperative myocar-
Figure 3. a, Changes in the percentage ratio of plasma nitrotyrosine to tyrosine (%NO2-Tyr) in the blood obtained
from aortic root (Ao) and coronary sinus (CS), before cardiopulmonary bypass and 5 minutes after aortic
unclamping. Data are expressed as mean  SD. *P < .0001; Ao vs CS after reperfusion. b, Comparisons of the
difference in %NO2-Tyr between coronary sinus effluent and arterial blood (CS-Ao in %NO2-Tyr) 5 minutes after
aortic unclamping. Data are expressed as mean  SD.
Figure 4. Relations between (a) the aortic crossclamping time (AXC time) and the difference in the percentage
ratio of plasma nitrotyrosine to tyrosine between coronary sinus effluent and arterial blood (CS-Ao in %NO2-Tyr)
5 minutes after aortic unclamping. Group LDTC: CS-Ao in %NO2-Tyr  0.351  0.021  AXC time (R
2  .809);
group CONT (LDTC ()): CS-Ao in %NO2-Tyr  1.834  0.039  AXC time (R
2  .871). Relations between (b) CS-Ao
in %NO2-Tyr and the difference in the plasma levels of polymorphonuclear-elastase (CS-Ao difference in PMNE)
5 minutes after aortic unclamping. Group LDTC: CS-Ao difference in %NO2-Tyr 0.441 0.029 CS-Ao difference
in PMNE (R2  .798); group CONT (LDTC ()): CS-Ao difference in %NO2-Tyr  0.116  0.023  [CS-Ao difference
in PMNE (R2  .672)].
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dial damage, and our results are consistent with the patho-
physiology of the development of myocardial ischemia-
reperfusion injury.
Leukocyte depletion during myocardial reperfusion at-
tenuates inflammatory responses mediated by the interac-
tion between neutrophils and coronary endothelial cells and
activated by neutrophil-produced chemotactic mediators.6-9
In this study, activated neutrophils were normothermically
perfused into the coronary vessels after aortic unclamping in
both groups. However, terminal cardioplegia is a kind of
warm blood perfusion even though infused to nonworking
hearts with cardioplegic arresting vehicles, and it is consid-
ered as a “warm-up” perfusion prior to aortic unclamping by
the acceleration of myocardial metabolic recovery and the
preservation of high-energy phosphate.25,26 In addition, the
first 10 minutes of reperfusion are the most critical period
TABLE 2. Clinical parameters associated with myocardial protection
Group CONT-S
(n  14)
Group LDTC-S
(n  13) P value
Group CONT-L
(n  13)
Group LDTC-L
(n  14) P value
Percentage ratio of spontaneous
defibrillation after aortic
unclamping (%)
78.6 84.6 .9999 30.8 78.6 .0213
Maximum dose of catecholamine
required during the postoperative
period (g/kg/min)
3.18 1.42 3.41 2.04 .7361 8.45 3.42 5.44 2.29 .0122
Figure 5. Comparisons of (a) the difference in plasma polymorphonuclear-elastase between coronary sinus
effluent and arterial blood 5 minutes after aortic unclamping (CS-Ao difference in PMNE); (b) the difference in
plasma malondialdehyde between coronary sinus effluent and arterial blood 5 minutes after aortic unclamping
(CS-Ao difference in MDA); (c) plasma human-heart fatty acid– binding protein in the arterial blood 45 minutes after
aortic unclamping (HH-FABP); and (d) peak plasma creatine kinase–muscle and brain during the first 24 postop-
erative hours (peak CK-MB). Data are expressed as mean  SD.
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for intraoperative myocardial protection.27-29 The major
morphological changes of subcellular levels are detected in
this period.27 Intracellular neutrophil hydrogen peroxide
begins to increase as early as 15 minutes,29 and Tsao and
colleagues28 demonstrated that peak free radical production
and subsequent endothelial damage occurred very early
after myocardial reperfusion. Regarding this pathophysio-
logical aspect, it is rational that leukocyte depletion during
terminal cardioplegia attenuated intraoperative myocardial
damage induced by subsequent reperfusion with activated
neutrophils.
The change in NO production during cardiac surgery is
considered an adaptive response to maintain systemic ho-
meostasis against myocardial ischemia and CPB-induced
inflammation, which is regulated by 2 kinds of NO synthase
(NOS).30,31 In the early period after CPB initiation or AXC,
endothelial-constitutive NOS (ecNOS) is activated to en-
hance endogenous NO production.30 In the late period,
ecNOS activity is gradually impaired and subsequent induc-
ible NOS (iNOS) expression compensates for the reduction
in endogenous NO production.31,32 However, abrupt myo-
cardial deterioration at reperfusion enhances the impairment
of ecNOS activity,15-17 resulting in the marked difference in
NOx in CS as shown in this study. Furthermore, the result
that plasma NOx was significantly higher in LDTC-treated
patients with AXC of 120 minutes or more supports the
hypothesis that intraoperative neutrophil activation is
largely associated with the impairment of ecNOS activity of
coronary endothelial cells.
NO derived from endothelium rapidly reacts and com-
bines with superoxide anion to form ONOO. On the other
hand, superoxide anion is released by endothelium and
neutrophils through the activation of NADH oxidase.
Therefore, a reduction in neutrophil activation and subse-
quent reduction in superoxide anion contributes to reduce
the production of potentially cytotoxic ONOO. This study
demonstrates that LDTC reduces neutrophil activation and
subsequent myocardium-derived ONOO production in pa-
tients requiring prolonged AXC.
Although the cytotoxicity of ONOO is considered
much greater than that of other free radicals,33-35 recent
experimental studies have demonstrated that ONOO plays
a cytoprotective role in the development of intraoperative
myocardial ischemia-reperfusion injury.36-38 Plasma
ONOO level only suggests the amount of superoxide
production and the degree of myocardial injury at present.
Further elucidations are needed to clarify the role of
ONOO in the development of myocardial ischemia-reper-
fusion injury under clinical circumstances.
In summary, we first demonstrated the myocardial pro-
tective effects of LDTC in association with NO and
ONOO production. This study has clearly demonstrated
that LDTC provides superior myocardial protective effects
and regulates myocardium-derived NO and ONOO pro-
duction only for patients undergoing more than 120 minutes
of AXC. These results suggest that prolonged AXC deteri-
orates the tolerance to neutrophil-mediated myocardial in-
jury accompanied by endothelial dysfunction associated
with NO and ONOO production.
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